Yang Xinghong, Hinnebusch B Joseph, Trunkle Theresa, Bosio Catharine M, Suo Zhiyong, Tighe Mike, Harmsen Ann, Becker Todd, Crist Kathryn, Walters Nancy, Avci Recep, Pascual David W
Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717, USA.
J Immunol. 2007 Jan 15;178(2):1059-67. doi: 10.4049/jimmunol.178.2.1059.
The gut provides a large area for immunization enabling the development of mucosal and systemic Ab responses. To test whether the protective Ags to Yersinia pestis can be orally delivered, the Y. pestis caf1 operon, encoding the F1-Ag and virulence Ag (V-Ag) were cloned into attenuated Salmonella vaccine vectors. F1-Ag expression was controlled under a promoter from the caf1 operon; two different promoters (P), PtetA in pV3, PphoP in pV4, as well as a chimera of the two in pV55 were tested. F1-Ag was amply expressed; the chimera in the pV55 showed the best V-Ag expression. Oral immunization with Salmonella-F1 elicited elevated secretory (S)-IgA and serum IgG titers, and Salmonella-V-Ag(pV55) elicited much greater S-IgA and serum IgG Ab titers than Salmonella-V-Ag(pV3) or Salmonella-V-Ag(pV4). Hence, a new Salmonella vaccine, Salmonella-(F1+V)Ags, made with a single plasmid containing the caf1 operon and the chimeric promoter for V-Ag allowed the simultaneous expression of F1 capsule and V-Ag. Salmonella-(F1+V)Ags elicited elevated Ab titers similar to their monotypic derivatives. For bubonic plague, mice dosed with Salmonella-(F1+V)Ags and Salmonella-F1-Ag showed similar efficacy (>83% survival) against approximately 1000 LD(50) Y. pestis. For pneumonic plague, immunized mice required immunity to both F1- and V-Ags because the mice vaccinated with Salmonella-(F1+V)Ags protected against 100 LD(50) Y. pestis. These results show that a single Salmonella vaccine can deliver both F1- and V-Ags to effect both systemic and mucosal immune protection against Y. pestis.
肠道提供了大面积的免疫区域,可促进黏膜和全身抗体反应的发展。为了测试鼠疫耶尔森菌的保护性抗原是否可以口服递送,将编码F1抗原和毒力抗原(V抗原)的鼠疫耶尔森菌caf1操纵子克隆到减毒沙门氏菌疫苗载体中。F1抗原的表达受caf1操纵子启动子的控制;测试了两种不同的启动子(P),pV3中的PtetA、pV4中的PphoP以及pV55中两者的嵌合体。F1抗原大量表达;pV55中的嵌合体显示出最佳的V抗原表达。用沙门氏菌-F1进行口服免疫可提高分泌型(S)-IgA和血清IgG滴度,并且沙门氏菌-V抗原(pV55)比沙门氏菌-V抗原(pV3)或沙门氏菌-V抗原(pV4)引发的S-IgA和血清IgG抗体滴度高得多。因此,一种新的沙门氏菌疫苗,即沙门氏菌-(F1+V)抗原,由含有caf1操纵子和V抗原嵌合启动子的单个质粒制成,可同时表达F1荚膜和V抗原。沙门氏菌-(F1+V)抗原引发的抗体滴度升高,与其单型衍生物相似。对于腺鼠疫,用沙门氏菌-(F1+V)抗原和沙门氏菌-F1抗原给药的小鼠对约1000个半数致死量(LD50)的鼠疫耶尔森菌显示出相似的疗效(存活率>83%)。对于肺鼠疫,免疫小鼠需要对F1抗原和V抗原都具有免疫力,因为用沙门氏菌-(F1+V)抗原接种的小鼠可抵御100个LD50的鼠疫耶尔森菌。这些结果表明,单一的沙门氏菌疫苗可以递送F1抗原和V抗原,以实现针对鼠疫耶尔森菌的全身和黏膜免疫保护。